Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.

Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Mol Pharm (2016) 0.81

In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development. Nat Commun (2016) 0.79

Common pathway signature in lung and liver fibrosis. Cell Cycle (2016) 0.77

Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors. Oncotarget (2017) 0.75

Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data. Cell Cycle (2017) 0.75

Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice. Aging (Albany NY) (2017) 0.75

Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods (1986) 12.51

The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49

Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther (2010) 2.38

Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol (2010) 1.58

Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front Genet (2014) 1.22

Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front Genet (2014) 1.10

Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cells. Aging (Albany NY) (2015) 1.08

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer (2012) 1.06

Signaling pathways activation profiles make better markers of cancer than expression of individual genes. Oncotarget (2014) 1.05

Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia (2014) 1.04

The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Front Mol Biosci (2014) 1.04

Pathway activation profiling reveals new insights into age-related macular degeneration and provides avenues for therapeutic interventions. Aging (Albany NY) (2014) 1.04

Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget (2014) 1.00

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Res Treat (2013) 0.91

Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer. Oncotarget (2014) 0.91

Enzymatic features of the glucose metabolism in tumor cells. FEBS J (2011) 0.88

miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol (2014) 0.88

Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Curr Cancer Drug Targets (2009) 0.87

Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. Cancer Lett (2013) 0.87

AXL as a modulator of sunitinib response in glioblastoma cell lines. Exp Cell Res (2015) 0.85

Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. Mol Ther (2015) 0.84

Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells. Prostate (2015) 0.83

Where cancer genomics should go next: a clinician's perspective. Hum Mol Genet (2014) 0.83

Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. Int J Mol Sci (2014) 0.82

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis (2011) 0.82

Altered radiation responses of breast cancer cells resistant to hormonal therapy. Oncotarget (2015) 0.82

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget (2015) 0.82

Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest. Cell Biol Int (2015) 0.81

Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. World J Clin Oncol (2014) 0.81

Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human. Oncotarget (2016) 0.77